Business
SCIB1 compelling survival data in melanoma
SCIB1 compelling survival data in melanoma.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3373D Scancell Holdings Plc 06 July 2016 \n\n6 July 2016\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nSCIB1 continues to deliver compelling survival data in melanoma \n \nScancell to present update at the Oxford Technology VCT AGM and Proactive Investors One2One Forum\n \nScancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, today provides an update from the SCIB1 Phase 1/2 clinical trial in malignant melanoma, the lead programme from the Company's ImmunoBody® platform and will be presenting at the Oxford Technology VCT AGM and Proactive Investors One2One Forum later this week. \n \nDr Richard Goodfellow, CEO of Scancell, said: \"SCIB1 continues to deliver compelling survival data in patients with resected Stage III/IV melanoma. It is particularly interesting to note that there has only been one new case of disease progression since November 2013 in the resected patients receiving 4mg doses of SCIB1, which gives us hope that SCIB1 might offer curative potential in this currently untreated patient group.\"\n \nDr Keith Flaherty, Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School, commented: \"The SCIB1 overall survival and progression free survival data generated to date go well beyond established norms for this group of melanoma patients. We have a lot of enthusiasm for validating these results in subsequent trials.\"\n \nSCIB1 Survival Update\n \nAs of 27 June 2016, SCIB1 continues to deliver strong survival data:\n \n· Currently 19 of the 20 patients with resected tumours at study entry remain alive\no One patient who first experienced disease progression in September 2013 died in April 2016, despite additional treatment with checkpoint inhibitors and radiation therapy\n· Of the 16 patients who received 2-4mg doses of SCIB1\no Median observation time since entry is 46 months and 52 months since first diagnosis of metastatic disease\no Only five patients have progressed and one has died\no Only one new incidence of disease progression has been seen since November 2013\n· &...